5.70
전일 마감가:
$5.84
열려 있는:
$5.57
하루 거래량:
764.76K
Relative Volume:
0.63
시가총액:
$293.47M
수익:
$3.64M
순이익/손실:
$-87.37M
주가수익비율:
-1.3869
EPS:
-4.11
순현금흐름:
$-86.46M
1주 성능:
-15.30%
1개월 성능:
+2.89%
6개월 성능:
+105.78%
1년 성능:
-52.42%
Verastem Inc Stock (VSTM) Company Profile
명칭
Verastem Inc
전화
(781) 292-4200
주소
117 KENDRICK STREET, NEEDHAM, MA
VSTM을(를) 다른 주식과 비교
주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
---|---|---|---|---|---|---|
![]()
VSTM
Verastem Inc
|
5.70 | 293.47M | 3.64M | -87.37M | -86.46M | -4.11 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
484.01 | 124.29B | 11.02B | -535.60M | -978.00M | -2.20 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
610.64 | 68.39B | 14.20B | 4.41B | 3.54B | 38.28 |
![]()
ARGX
Argen X Se Adr
|
590.06 | 35.99B | 2.19B | 833.04M | -1.28B | 12.71 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
262.16 | 33.93B | 2.25B | -278.16M | -42.59M | -2.17 |
![]()
ONC
Beigene Ltd Adr
|
264.32 | 28.47B | 3.81B | -644.79M | -669.77M | -6.24 |
Verastem Inc Stock (VSTM) Upgrades & Downgrades
날짜 | 액션 | 분석자 | 등급 변경 |
---|---|---|---|
2025-03-24 | 재확인 | H.C. Wainwright | Buy |
2024-12-31 | 재확인 | BTIG Research | Buy |
2024-09-30 | 개시 | Guggenheim | Buy |
2023-11-21 | 재개 | BTIG Research | Buy |
2023-09-27 | 개시 | B. Riley Securities | Buy |
2023-06-15 | 업그레이드 | Mizuho | Neutral → Buy |
2022-09-07 | 재개 | Alliance Global Partners | Buy |
2022-04-29 | 재개 | Cantor Fitzgerald | Overweight |
2022-04-14 | 개시 | RBC Capital Mkts | Outperform |
2022-03-09 | 개시 | Truist | Buy |
2021-07-01 | 개시 | Alliance Global Partners | Buy |
2021-05-24 | 업그레이드 | BTIG Research | Neutral → Buy |
2019-06-20 | 다운그레이드 | BTIG Research | Buy → Neutral |
2019-05-10 | 다운그레이드 | Raymond James | Outperform → Mkt Perform |
2018-07-13 | 개시 | BTIG Research | Buy |
2018-05-02 | 개시 | Seaport Global Securities | Buy |
2018-03-08 | 개시 | B. Riley FBR, Inc. | Buy |
2017-09-07 | 재확인 | H.C. Wainwright | Buy |
2017-04-13 | 개시 | Oppenheimer | Outperform |
2017-03-24 | 재확인 | H.C. Wainwright | Buy |
2015-09-29 | 다운그레이드 | Cantor Fitzgerald | Buy → Hold |
2015-09-29 | 다운그레이드 | JMP Securities | Mkt Outperform → Mkt Perform |
2015-09-29 | 다운그레이드 | Jefferies | Buy → Hold |
2015-09-29 | 다운그레이드 | Raymond James | Strong Buy → Outperform |
2015-09-28 | 다운그레이드 | Mizuho | Buy → Neutral |
2015-09-28 | 다운그레이드 | ROTH Capital | Buy → Neutral |
2015-09-09 | 개시 | Raymond James | Strong Buy |
2015-05-12 | 재확인 | UBS | Buy |
2015-04-08 | 개시 | H.C. Wainwright | Buy |
2015-01-23 | 재확인 | ROTH Capital | Buy |
2014-07-08 | 재개 | Oppenheimer | Perform |
2014-02-11 | 개시 | Mizuho | Buy |
모두보기
Verastem Inc 주식(VSTM)의 최신 뉴스
Verastem Oncology Reports Progress in Cancer Treatments - TipRanks
Verastem (NASDAQ:VSTM) Upgraded at StockNews.com - MarketBeat
Wall Street Analysts Believe Verastem (VSTM) Could Rally 100.94%: Here's is How to Trade - Yahoo Finance
(VSTM) Technical Pivots with Risk Controls - news.stocktradersdaily.com
Verastem Oncology Announces Multiple Presentations Focused on RAS/MAPK Pathway Inhibition at AACR Annual Meeting 2025 - Yahoo Finance
Verastem CFO Daniel Calkins sells shares worth $630 - Investing.com India
Verastem CFO Daniel Calkins sells shares worth $630 By Investing.com - Investing.com Australia
H.C. Wainwright lifts Verastem stock price target to $10 By Investing.com - Investing.com Canada
Guggenheim lifts Verastem stock target to $14, maintains buy By Investing.com - Investing.com Canada
H.C. Wainwright lifts Verastem stock price target to $10 - Investing.com India
Royal Bank of Canada Lowers Verastem (NASDAQ:VSTM) Price Target to $14.00 - Defense World
RBC Cuts Price Target on Verastem to $14 From $16, Maintains Outperform Rating -March 21, 2025 at 08:40 am EDT - Marketscreener.com
BTIG maintains $20 target, Buy rating on Verastem stock By Investing.com - Investing.com Canada
Verastem: Q4 Earnings Snapshot - Midland Daily News
Verastem director Brian Stuglik sells shares worth $4,121 By Investing.com - Investing.com Australia
Verastem Unveils Strategic Plans in New Presentation - TipRanks
Verastem Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Verastem, Inc. SEC 10-K Report - TradingView
Verastem Inc. (VSTM) reports earnings - Quartz
Verastem Oncology Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Business Updates - Bluefield Daily Telegraph
Verastem director Robert Gagnon sells shares worth $1,973 By Investing.com - Investing.com Australia
Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
Verastem, Inc. (NASDAQ:VSTM) Receives Consensus Rating of “Buy” from Brokerages - Defense World
Verastem CEO sells shares worth $1,695 By Investing.com - Investing.com South Africa
Verastem director Robert Gagnon sells shares worth $1,973 - Investing.com
Verastem director Brian Stuglik sells shares worth $4,121 - Investing.com
Verastem (NASDAQ:VSTM) Stock Passes Above 200-Day Moving Average – Here’s Why - Defense World
Hallador Energy, Tesla And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session - Benzinga
Verastem Inc expected to post a loss of 81 cents a shareEarnings Preview - TradingView
Verastem to Present at Keystone Symposia on PI3 Kinase - AOL.com
Verastem: Upcoming PDUFA, But I Remain Cautious (NASDAQ:VSTM) - Seeking Alpha
Rhumbline Advisers Acquires 10,352 Shares of Verastem, Inc. (NASDAQ:VSTM) - Defense World
Why the Global Cancer Market Could Surpass $900 Billion-And the Stocks Leading the Charge - The Malaysian Reserve
Why the Global Cancer Market Could Surpass $900 Billion—And the Stocks Leading the Charge - Morningstar
Verastem (VSTM) Expected to Announce Earnings on Thursday - Defense World
Objective long/short (VSTM) Report - Stock Traders Daily
Verastem Inc (NASDAQ: VSTM) Stock Forecast: Bearish Expectations Portend -120.34% Downside In 2025 - Stocks Register
Verastem (NASDAQ:VSTM) Stock Price Passes Above 200 Day Moving Average – Should You Sell? - Defense World
Verastem, Inc. (NASDAQ:VSTM) Given Consensus Rating of “Buy” by Brokerages - Defense World
Verastem Oncology Announces Multiple Data Presentations At Society Of Gynecologic Oncology 2025 Annual Meeting On Women's Cancer - Marketscreener.com
Verastem Oncology Announces Multiple Data Presentations at Society of Gynecologic Oncology 2025 Annual Meeting on Women’s Cancer - Business Wire
VSTM Up as NDA for Ovarian Cancer Combo Gets FDA's Priority Review Tag - MSN
When the Price of (VSTM) Talks, People Listen - Stock Traders Daily
Financial Snapshot: Analyzing Verastem Inc (VSTM)’s Key Ratio Metrics - The Dwinnex
Verastem Inc (NASDAQ: VSTM) Shares Fall By -4.77 Percent In The Past Week, But How Long Will It Last? - Marketing Sentinel
Verastem Inc (VSTM) 재무 분석
매출
순이익
현금흐름
주당 순 이익
자본화:
|
볼륨(24시간):